Hyperhomocysteinemia and dyslipidemia in point mutation G307S of cystathionine β-synthase-deficient rabbit generated

Ting Zhang1,2, Rui Lu3, Yibing Chen1,2

  • 1College of Veterinary Medicine, Yangzhou University, Yangzhou, 225009, Jiangsu, China.

Insights

A genetic mutation in the cystathionine β-synthase (CBS) gene causes congenital hyper-homocysteinemia (HHcy) and severe dyslipidemia in rabbits. Supplementation with vitamin B and betaine improved lipid levels and liver health.

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Animal Models

Background:

  • Congenital hyper-homocysteinemia (HHcy) is linked to cystathionine β-synthase (CBS) gene defects and often co-occurs with dyslipidemia.
  • Understanding the precise impact of CBS mutations on lipid metabolism is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the effects of a specific CBS gene mutation (G307S) on circulating lipids.
  • To establish and characterize a rabbit model of HHcy-induced dyslipidemia.

Main Methods:

  • CRISPR/Cas9 gene editing was employed to create CBS-knockout (CBS-KO) rabbits with a G307S mutation.
  • Plasma homocysteine (Hcy) and lipid profiles (triglycerides, total cholesterol, LDL-C) were analyzed in CBS-KO and wild-type (WT) rabbits.
  • Hepatic lipid accumulation was assessed via histological analysis.

Main Results:

  • CBS-KO rabbits exhibited significant growth retardation, high mortality, and elevated plasma Hcy, triglycerides, total cholesterol, and LDL-C compared to WT controls.
  • Histological examination revealed micro-vesicular cytoplasmic lipid droplets in the hepatocytes of CBS-KO rabbits, indicating hepatic steatosis.
  • Gastric administration of vitamin B and betaine complex successfully reduced plasma lipid levels and alleviated hepatic steatosis in CBS-KO rabbits.

Conclusions:

  • The generated CBSG307S rabbit model effectively recapitulates HHcy-associated dyslipidemia on a standard diet.
  • The G307S mutation in the CBS gene is confirmed as a causative factor for severe dyslipidemia.
  • Vitamin B and betaine supplementation show therapeutic potential for managing HHcy-related metabolic disturbances.
Abstract